The stock of Kindred Biosciences Inc (NASDAQ:KIN) is a huge mover today! About 865,658 shares traded hands or 1099.74% up from the average. Kindred Biosciences Inc (NASDAQ:KIN) has risen 46.01% since March 3, 2016 and is uptrending. It has outperformed by 37.67% the S&P500.
The move comes after 7 months negative chart setup for the $107.97 million company. It was reported on Oct, 6 by Barchart.com. We have $4.40 PT which if reached, will make NASDAQ:KIN worth $14.04 million less.
Analysts await Kindred Biosciences Inc (NASDAQ:KIN) to report earnings on November, 14. They expect $-0.36 EPS, 0.00% or $0.00 from last year’s $-0.36 per share. After $-0.25 actual EPS reported by Kindred Biosciences Inc for the previous quarter, Wall Street now forecasts 44.00% negative EPS growth.
According to Zacks Investment Research, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.”
Insitutional Activity: The institutional sentiment increased to 3.13 in Q2 2016. Its up 2.48, from 0.65 in 2016Q1. The ratio improved, as 3 funds sold all Kindred Biosciences Inc shares owned while 5 reduced positions. 4 funds bought stakes while 21 increased positions. They now own 25.54 million shares or 107.22% more from 12.33 million shares in 2016Q1.
Connor Clark & Lunn Investment Limited has 0% invested in the company for 62,725 shares. Moreover, Old West Management Ltd Liability has 0.12% invested in Kindred Biosciences Inc (NASDAQ:KIN) for 46,428 shares. Dimensional Fund Advsrs L P reported 22,754 shares or 0% of all its holdings. The Massachusetts-based Geode Capital has invested 0% in Kindred Biosciences Inc (NASDAQ:KIN). Walleye Trading Limited Liability Company accumulated 0% or 800 shares. Blackrock Fund Advsr, a California-based fund reported 42,936 shares. Blackrock Japan Limited has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Grt Cap Partners Limited Liability Corp holds 62,300 shares or 0.05% of its portfolio. Wells Fargo And Mn reported 2,989 shares or 0% of all its holdings. Baupost Ltd Liability Ma, a Massachusetts-based fund reported 3.01 million shares. Ecor1 Cap Ltd Llc holds 2% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 1.43M shares. Bridgeway Mgmt accumulated 0% or 80,300 shares. Lpl Financial Llc holds 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 13,925 shares. Mufg Americas Hldg Corp has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Norman Fields Gottscho Cap Management Lc holds 0.03% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 13,900 shares.
More notable recent Kindred Biosciences Inc (NASDAQ:KIN) news were published by: Prnewswire.com which released: “Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference” on September 20, 2016, also Prnewswire.com with their article: “Kindred Biosciences to Participate in a BIO Animal Biotech Summit Panel” published on September 15, 2016, Prnewswire.com published: “Kindred Biosciences Announces Second Quarter 2016 Financial Results” on August 08, 2016. More interesting news about Kindred Biosciences Inc (NASDAQ:KIN) were released by: Quotes.Wsj.com and their article: “News Kindred Biosciences Inc.KIN” published on December 07, 2013 as well as Prnewswire.com‘s news article titled: “Kindred Biosciences Receives Approval of Effectiveness Technical Section from …” with publication date: October 04, 2016.
KIN Company Profile
Kindred Biosciences, Inc., incorporated on September 25, 2012, is a development-stage biopharmaceutical company. The Firm is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Firm is developing product candidates for over 20 indications and focused on small molecule products, and canine and feline biologics products. The Company’s biologic product candidates are based on therapies and targets, for which products have been commercialized for humans. The Firm is developing antibodies that target canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.